89bio, Inc. (ETNB) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
89bio, Inc.
Address
142 Sansome Street
San Francisco, CA 94104
United States of America (the)
Phone
415 432 9270
Website
Sector
Healthcare
Industry
Biotechnology
Employees
93
First IPO Date
November 11, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Rohan Palekar | Chief Executive Officer & Director | 999,834 | 1966 |
| Francis W. Sarena | Chief Operating Officer | 590,473 | 1971 |
| Ryan Stephen Martins | Chief Financial Officer | 646,525 | 1978 |
| Quoc Le-Nguyen | Chief Technical Officer | 693,099 | 1968 |
| Harry Mansbach | Chief Medical Officer | 717,383 | 1965 |
| Shiva K. Natarajan | Senior Vice President of Finance & Principal Accounting Officer | 0 | 1966 |
| Teresa Perney | Chief Regulatory & Quality Officer | 0 | N/A |
| Michael Baldwin | Senior Vice President & Head of Quality | 0 | N/A |
| Amanda Kurihara | Vice President of People & Culture | 0 | N/A |
| Annie J. Chang | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Melissa Abel | Senior Vice President of Commercial Strategy | 0 | N/A |
Description
Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia. Founded in 2018, 89bio, Inc. maintains its corporate headquarters in San Francisco, California.
